GSK620 Is an orally active, potent and selective pan-second bromodomain (BD2) inhibitor (BD2/BD1 pIC50 = 6.5/4.6/BRD2, 7.1/4.6/BRD3, 7.1/4.8/BRD4, 6.7/4.6/BRDT) with improved oral availability than GSK046 (iBET-BD2) and in vivo efficacy in inflammatory disease models, including collagen-induced arthritis (3-10 mg/kg/d p.o. in rats), imiquimod (IMQ)-induced psoriasis (20 mg/kg/d p.o. in mice), and a nonalcoholic steatohepatitis (NAFLD) model (20 mg/kg/d p.o. in STAM mice).
Potent and selective pan-second bromodomain (BD2) inhibitor with in vivo efficacy in inflammatory disease models and improved oral availability than GSK046.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.